These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 19799469)
1. Value-based insurance design in Medicare. Encinosa WE Appl Health Econ Health Policy; 2009; 7(3):149-54. PubMed ID: 19799469 [TBL] [Abstract][Full Text] [Related]
2. Value-based insurance design: embracing value over cost alone. Fendrick AM; Chernew ME; Levi GW Am J Manag Care; 2009 Dec; 15(10 Suppl):S277-83. PubMed ID: 20088631 [TBL] [Abstract][Full Text] [Related]
3. Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies. Sensharma A; Yabroff KR Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):263-277. PubMed ID: 30628493 [TBL] [Abstract][Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries. Goedken AM; Urmie JM; Farris KB; Doucette WR Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109 [TBL] [Abstract][Full Text] [Related]
5. Value-Based Insurance Design Improves Medication Adherence Without An Increase In Total Health Care Spending. Agarwal R; Gupta A; Fendrick AM Health Aff (Millwood); 2018 Jul; 37(7):1057-1064. PubMed ID: 29985690 [TBL] [Abstract][Full Text] [Related]
6. Value-based insurance design: quality improvement but no cost savings. Lee JL; Maciejewski M; Raju S; Shrank WH; Choudhry NK Health Aff (Millwood); 2013 Jul; 32(7):1251-7. PubMed ID: 23836741 [TBL] [Abstract][Full Text] [Related]
7. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105 [TBL] [Abstract][Full Text] [Related]
8. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies. Carroll NV J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295 [TBL] [Abstract][Full Text] [Related]
9. Can broader diffusion of value-based insurance design increase benefits from US health care without increasing costs? Evidence from a computer simulation model. Braithwaite RS; Omokaro C; Justice AC; Nucifora K; Roberts MS PLoS Med; 2010 Feb; 7(2):e1000234. PubMed ID: 20169114 [TBL] [Abstract][Full Text] [Related]
10. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis. Tseng CW; Dudley RA; Chen R; Walensky RP JAMA Netw Open; 2020 Apr; 3(4):e202739. PubMed ID: 32286656 [TBL] [Abstract][Full Text] [Related]
11. Value-based insurance design: barriers to implementation in radiology. Kelly AM; Cronin P Acad Radiol; 2011 Sep; 18(9):1115-22. PubMed ID: 21680205 [TBL] [Abstract][Full Text] [Related]
12. The effect of a large regional health plan's value-based insurance design program on statin use. Frank MB; Fendrick AM; He Y; Zbrozek A; Holtz N; Leung S; Chernew ME Med Care; 2012 Nov; 50(11):934-9. PubMed ID: 23047782 [TBL] [Abstract][Full Text] [Related]
13. Value-based insurance design program in north Carolina increased medication adherence but was not cost neutral. Maciejewski ML; Wansink D; Lindquist JH; Parker JC; Farley JF Health Aff (Millwood); 2014 Feb; 33(2):300-8. PubMed ID: 24493774 [TBL] [Abstract][Full Text] [Related]
14. Five features of value-based insurance design plans were associated with higher rates of medication adherence. Choudhry NK; Fischer MA; Smith BF; Brill G; Girdish C; Matlin OS; Brennan TA; Avorn J; Shrank WH Health Aff (Millwood); 2014 Mar; 33(3):493-501. PubMed ID: 24522551 [TBL] [Abstract][Full Text] [Related]
15. How do seniors respond to 100% cost-sharing for prescription drugs? Quality of the evidence underlying opinions about the Medicare Part D coverage gap. Fairman KA; Curtiss FR J Manag Care Pharm; 2011 Jun; 17(5):382-92. PubMed ID: 21657807 [TBL] [Abstract][Full Text] [Related]
16. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter? Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540 [TBL] [Abstract][Full Text] [Related]
17. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs. Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239 [TBL] [Abstract][Full Text] [Related]
18. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. Dusetzina SB; Conti RM; Yu NL; Bach PB JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108 [TBL] [Abstract][Full Text] [Related]
19. Increasing Medicare part D enrollment in medication therapy management could improve health and lower costs. Stuart B; Loh FE; Roberto P; Miller LM Health Aff (Millwood); 2013 Jul; 32(7):1212-20. PubMed ID: 23836736 [TBL] [Abstract][Full Text] [Related]
20. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis. Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]